Lincoln International’s Global Healthcare Group Announces Strong Results in 2022
Lincoln International’s global Healthcare Group enjoyed another consecutive year of record-setting mergers and acquisitions (M&A) deal volume, average deal size and a record backlog heading in to 2023. Our performance is especially notable given global healthcare M&A volumes saw a modest pull back in 2022 brought on by instability in the labor market, higher inflation and interest rates, pressure on reimbursements and the waning influence of COVID-19-era government-funded supports.
Despite these macro influences, we expect 2023 to be another active year for healthcare dealmaking as industry players and private equity utilize M&A as a strategy to keep pace with the ever-increasing complexities across healthcare access, quality and cost; regulatory pressures; reimbursement rates; software and technology integration; payment reforms and advances in pharma and medical technology.
Our team has deep domain expertise and transaction experience across a number of high growth areas of the global healthcare economy including:
- Animal health
- Behavioral and mental health
- Fertility and women’s health
- Healthcare IT and tech-enabled services
- Home and community based care
- Labs and lab services
- Payor services and employer-funded insurance services
- Pharma and medtech outsourcing
- Physical / occupational / speech therapy and rehab
- Physician services and ambulatory care
- Value-based care enablement
- Revenue cycle management
Summary
-
Lincoln International's Global Healthcare Group announces strong results in 2022.
Select Notable 2022 Healthcare Transactions
Related Perspectives
PETS International | Consolidation Meets Regulation in the Veterinary Clinics Market
Originally posted by PETS International on April 5, 2024. Animal health is becoming a big business in Europe and the U.S. Thus, regulators are turning a closer eye to mergers… Read More
“Leader to Leader” Series
The Leader to Leader video series turns up the dial on rich conversations with prominent leaders – from business owners and entrepreneurs to investors and CEOs – highlighting their stories… Read More
What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access
The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More
Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal
The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More
Meet Our Senior Team in Healthcare
I enjoy working closely with clients to overcome challenging situations and to develop strategies to meet their business goals.
Dirk-Oliver Löffler
Managing Director | European Co-head Healthcare
Frankfurt
